New 'Sandwich' strategy aims to stop leukemia relapse after CAR-T

NCT ID NCT06985498

Terminated Disease control Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a new treatment plan for teenagers and adults with B-cell acute lymphoblastic leukemia. Patients receive immunotherapy before a stem cell transplant using their own cells, followed by a CD22/CD19 CAR-T 'sandwich' to reduce the risk of relapse. The study aims to see if this approach is safe and improves survival. It is currently suspended.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD22/CD19 CAR-T cells, CD19-directed T-cell engager, and inotuzumab ozogamicin
What this could lead to: If successful, this approach could lower the chance of leukemia returning after CAR-T therapy and stem cell transplant.
What could go wrong: This is a small, early-phase trial that is currently suspended. The combination therapy may cause severe side effects, and it is not yet known if it works better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBKASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia B-cell acute lymphoblastic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBKASTIC LEUKEMIA

Contacts and locations

Locations

The First Affiliated Hospital of Soochow University

Suzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.